Evidence map›Paper›PMID 34483742›Full record

ArticleMateria socio-medica2021

Hematopoietic Stem Cell Transplantation During the Era of COVID-19 in Queen Rania Children's Hospital.

Mousa Qatawneh, Mais Aljazazi, Moath Altarawneh, Hadeel Aljamaen, Maher Mustafa, Alaa Alqasem, Amjad Abu Sharar

Open access · hybridAbstract read
In one paragraph

Article in Materia socio-medica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Mousa QatawnehDepartment of Pediatric Hematology and Medical Oncology, Queen Rania Children's Hospital. Queen Rania AL- Abdullah children Hospital (QRCH), Jordan.
Mais AljazaziDepartment of Pediatric Hematology and Medical Oncology, Queen Rania Children's Hospital. Queen Rania AL- Abdullah children Hospital (QRCH), Jordan.
Moath AltarawnehDepartment of Pediatric Hematology and Medical Oncology, Queen Rania Children's Hospital. Queen Rania AL- Abdullah children Hospital (QRCH), Jordan.
Hadeel AljamaenConferences Office, King Hussein Medical City. Jordan.
Maher MustafaDepartment of Pediatric Hematology and Medical Oncology, Queen Rania Children's Hospital. Queen Rania AL- Abdullah children Hospital (QRCH), Jordan.
Alaa AlqasemDepartment of Pediatric Hematology and Medical Oncology, Queen Rania Children's Hospital. Queen Rania AL- Abdullah children Hospital (QRCH), Jordan.
Amjad Abu ShararDepartment of Pediatric Hematology and Medical Oncology, Queen Rania Children's Hospital. Queen Rania AL- Abdullah children Hospital (QRCH), Jordan.
Queen Mary's Hospital For Children · GBKing Hussein Medical Center · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCorona virus disease 2019 (COVID-19) is causing a health crisis nowadays, and all countries are following the recommendations of the WHO to decrease the spread of the disease. Till now, few data are available regarding the clinical course, severity of the disease and the duration of infectivity of COVID-19 in patients received Hematopoietic Stem Cell Transplantation (HSCT).

objectiveTo evaluate the medical protocols and outcome of patients who underwent HSCT during the pandemic of COVID-19.

methodsA retrospective review of the medical files of patients who underwent hematopoietic stem cell transplantation during the era of COVID-19. The following data were reviewed for all patients: age, gender, primary disease, viral screening protocols for donors and recipients, COVID-19 status and outcome. The European society for blood and marrow transplantation (EBMT) guidelines were applied strictly on all of our patients, donors and bone marrow transplant unit staff.

resultsA total of 10 children were transplanted, 8 of them received allogenic transplant from matched donor and two patients received autologous transplant. Regarding allogenic transplants, all of our patients except two were transplanted as an emergency, 2 of them were Aplastic anemia, 2 patients were Fanconi anemia, one patient was Amegakaryocytic thrombocytopenia, and one patient was Acute myeloid leukemia. Only two patients were not an emergency as one of them had Thalassemia major and the other one was Sickle cell anemia. The autologous transplant was done for two patients with Neuroblastoma stage 4 as part of their treatment protocol. At a median follow up of 5.5 months (range, 2 month-7 months) two patients (20%) developed COVID-19, which was asymptomatic in both of them. One of our patients (10%) died due to cytomegalovirus (CMV) pneumonia. No one of our patient was affected by the emergency regulations applied by the country and hospitals during the pandemic of COVID-19 virus.

conclusionHematopoietic stem cell transplantation can be performed safely for emergency cases, if we strictly follow the guidelines of EBMT.

Indexed as

COVID-19Hematopoietic stem cell transplantation

Identifiers

PMID34483742
PMCPMC8385744
OpenAlexW3195606194

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.